Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC).

Next Previous
Trial Profile

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary) ; Glatiramer acetate; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms EPOC
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 21 Apr 2016 Results (pooled subgroup analysis of this and other trial, n = 1420), assessing first-dose effects of fingolimod on cardiac outcomes in patients taking SSRIs presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 30 May 2013 Primary endpoint 'Significant difference between fingolimod and interferon beta or glatiramer acetate in Treatment-Satisfaction-Questionnaire-for-Medication score at 6 months' has been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top